Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects.

Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ.

BMC Infect Dis. 2011 Sep 17;11:244. doi: 10.1186/1471-2334-11-244.

2.

Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa.

Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM.

J Int AIDS Soc. 2012 Mar 12;15(1):13. doi: 10.1186/1758-2652-15-13.

3.

Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.

Dlamini J, Ledwaba L, Mokwena N, Mokhathi T, Orsega S, Tsoku M, Kowo H, Proschan M, Khabo P, Maja P, Hadigan C.

Antivir Ther. 2011;16(4):605-9. doi: 10.3851/IMP1790.

PMID:
21685549
4.

Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.

Palmer M, Chersich M, Moultrie H, Kuhn L, Fairlie L, Meyers T.

AIDS. 2013 Mar 13;27(5):781-5. doi: 10.1097/QAD.0b013e32835c54b8.

PMID:
23169331
5.

Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.

Brennan AT, Maskew M, Ive P, Shearer K, Long L, Sanne I, Fox MP.

J Int AIDS Soc. 2013 Nov 19;16:18794. doi: 10.7448/IAS.16.1.18794.

6.
7.

Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda.

Sacktor N, Nakasujja N, Skolasky RL, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB.

Neurology. 2009 Jan 13;72(2):165-70. doi: 10.1212/01.wnl.0000339042.96109.86.

8.

Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa.

Pahuja M, Grobler A, Glesby MJ, Karim F, Parker G, Gumede S, Naidoo K.

Antivir Ther. 2012;17(4):737-43. doi: 10.3851/IMP2087. Epub 2012 Mar 13.

9.

Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study.

Phan V, Thai S, Choun K, Lynen L, van Griensven J.

PLoS One. 2012;7(1):e30647. doi: 10.1371/journal.pone.0030647. Epub 2012 Jan 27.

10.

Hyperlactataemia during antiretroviral therapy: incidences, clinical data and treatment.

Gérard Y, Viget N, Yazdanpanah Y, Ajana F, de La Tribonnière X, Bocket L, Deuffic-Burban S, Dos Santos A, Ballester L, Mouton Y.

Therapie. 2003 Mar-Apr;58(2):153-8.

PMID:
12942856
11.

Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.

Castelnuovo B, Kiragga A, Kamya MR, Manabe Y.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):59-63. doi: 10.1097/QAI.0b013e3181f5bd03.

PMID:
20861741
12.

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

Ribera E, Paradiñeiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, Puiggròs C, Crespo M, Feijoo M, Diaz M, Del Saz SV, Planas M, Sureda D, Falcó V, Ocaña I, Pahissa A.

HIV Clin Trials. 2008 Nov-Dec;9(6):407-17. doi: 10.1310/hct0906-407.

PMID:
19203906
13.

Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy.

Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P, Funk MJ, Kaufman JS, Van Rie A, Macphail P.

Clin Infect Dis. 2009 Jun 1;48(11):1617-23. doi: 10.1086/598977.

15.

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.

Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L; Médecins Sans Frontieres..

AIDS. 2006 May 12;20(8):1163-9.

PMID:
16691068
16.

Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.

Lactic Acidosis International Study Group..

AIDS. 2007 Nov 30;21(18):2455-64. Review.

PMID:
18025882
17.

Stavudine-induced hyperlactatemia/lactic acidosis at a tertiary communicable diseases clinic in South Africa.

Hernández Pérez E, Dawood H.

J Int Assoc Physicians AIDS Care (Chic). 2010 Mar-Apr;9(2):109-12. doi: 10.1177/1545109710361536.

PMID:
20484736
18.

Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa.

Stead D, Osler M, Boulle A, Rebe K, Meintjes G.

Antivir Ther. 2008;13(7):937-43.

PMID:
19043928
19.

A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.

Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):150-7. doi: 10.1097/QAI.0b013e318251aedd.

20.

Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.

Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenal B, Lai AR, Saghayam S, Balakrishnan P, Yepthomi T, Poongulali S, Flanigan TP, Solomon S, Mayer KH.

AIDS Patient Care STDS. 2008 Apr;22(4):337-44. doi: 10.1089/apc.2007.0093.

PMID:
18422462

Supplemental Content

Support Center